Lancet: New Insights on Reducing Maternal Mortality

An inexpensive generic medicine, tranexamic acid, has been found in a major trial (known as the "World Maternal Antifibrinolytic", or WOMAN, Trial) to reduce maternal bleeding deaths by a third if administered within three hours. The six-year trial involved more than 20,000 women in 21 countries. Tranexamic acid, a blood-clotting medicine invented more than 60 years ago, costs less than $2 a dose and does not require refrigeration.  The trial was led by doctors at the London School of Hygiene and Tropical Medicine and paid for by the Wellcome Trust, Pfizer, Britain’s health department and the Bill and Melinda Gates Foundation. Results were published in The Lancet on Wednesday and were reported by the New York Times here

May 2017